This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $109.02 in the latest trading session, marking a +1.63% move from the prior day.
Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates
by Kinjel Shah
AbbVie's (ABBV) Skyrizi succeeds in psoriatic arthritis and Crohn's disease studies. AstraZeneca (AZN), Pfizer (PFE) and Roche (RHHBY) give FDA updates.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.
3 Biotech Technological Developments to Watch Out For in 2021
by Kinjel Shah
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Why AbbVie (ABBV) Could Beat Earnings Estimates Again
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $106.50 in the latest trading session, marking a +1.03% move from the prior day.
Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate
by Zacks Equity Research
Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, NVIDIA, Cisco, AbbVie and Sony
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $104.70 in the latest trading session, marking a +1.21% move from the prior day.
Top Analyst Reports for Johnson & Johnson, NVIDIA & Cisco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NVIDIA Corporation (NVDA) and Cisco Systems, Inc. (CSCO).
Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix
by Zacks Equity Research
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.
AbbVie (ABBV) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
by Zacks Equity Research
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $102.80 in the latest trading session, marking a -0.88% move from the prior day.
3 Stocks with Strong Dividends to Buy for Growth in 2021
by Benjamin Rains
Investors might want to consider adding stocks to their 2021 portfolios that pay a solid dividend and provide exposure to growth areas...
Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?
by Zacks Equity Research
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $104.64, marking a +1.77% move from the previous day.
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
by Zacks Equity Research
Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.
AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion
by Zacks Equity Research
AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.
3 Large-Cap Dividend Stocks to Buy and Hold Before 2021
by Benjamin Rains
Investors might not want to jump into stocks that are banking on a highly successful vaccine rollout. Therefore, we focused on 3 large-cap giants from completely different industries that pay a dividend and look poised to grow no matter what happens...
Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates
by Kinjel Shah
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.